1
|
Yundung Y, Mohammed S, Paneni F, Reutersberg B, Rössler F, Zimmermann A, Pelisek J. Transcriptomics analysis of long non-coding RNAs in smooth muscle cells from patients with peripheral artery disease and diabetes mellitus. Sci Rep 2024; 14:8615. [PMID: 38616192 PMCID: PMC11016542 DOI: 10.1038/s41598-024-59164-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Accepted: 04/08/2024] [Indexed: 04/16/2024] Open
Abstract
Diabetes mellitus (DM) is a significant risk factor for peripheral arterial disease (PAD), and PAD is an independent predictor of cardiovascular disorders (CVDs). Growing evidence suggests that long non-coding RNAs (lncRNAs) significantly contribute to disease development and underlying complications, particularly affecting smooth muscle cells (SMCs). So far, no study has focused on transcriptome analysis of lncRNAs in PAD patients with and without DM. Tissue samples were obtained from our Vascular Biobank. Due to the sample's heterogeneity, expression analysis of lncRNAs in whole tissue detected only ACTA2-AS1 with a 4.9-fold increase in PAD patients with DM. In contrast, transcriptomics of SMCs revealed 28 lncRNAs significantly differentially expressed between PAD with and without DM (FDR < 0.1). Sixteen lncRNAs were of unknown function, six were described in cancer, one connected with macrophages polarisation, and four were associated with CVDs, mainly with SMC function and phenotypic switch (NEAT1, MIR100HG, HIF1A-AS3, and MRI29B2CHG). The enrichment analysis detected additional lncRNAs H19, CARMN, FTX, and MEG3 linked with DM. Our study revealed several lncRNAs in diabetic PAD patients associated with the physiological function of SMCs. These lncRNAs might serve as potential therapeutic targets to improve the function of SMCs within the diseased tissue and, thus, the clinical outcome.
Collapse
Affiliation(s)
- Yankey Yundung
- Experimental Vascular Surgery/Department of Vascular Surgery, University Hospital Zurich/University of Zurich, Schlieren, Switzerland
| | - Shafeeq Mohammed
- Department of Cardiology/Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich/University of Zurich, Schlieren, Switzerland
| | - Francesco Paneni
- Department of Cardiology/Center for Translational and Experimental Cardiology (CTEC), University Hospital Zurich/University of Zurich, Schlieren, Switzerland
| | - Benedikt Reutersberg
- Experimental Vascular Surgery/Department of Vascular Surgery, University Hospital Zurich/University of Zurich, Schlieren, Switzerland
| | - Fabian Rössler
- Department of Surgery and Transplantation, University Hospital Zurich, Zürich, Switzerland
| | - Alexander Zimmermann
- Experimental Vascular Surgery/Department of Vascular Surgery, University Hospital Zurich/University of Zurich, Schlieren, Switzerland
| | - Jaroslav Pelisek
- Experimental Vascular Surgery/Department of Vascular Surgery, University Hospital Zurich/University of Zurich, Schlieren, Switzerland.
| |
Collapse
|
2
|
Mhaimeed O, Pillai K, Dargham S, Al Suwaidi J, Jneid H, Abi Khalil C. Type 2 diabetes and in-hospital sudden cardiac arrest in ST-elevation myocardial infarction in the US. Front Cardiovasc Med 2023; 10:1175731. [PMID: 37465457 PMCID: PMC10351872 DOI: 10.3389/fcvm.2023.1175731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Accepted: 05/31/2023] [Indexed: 07/20/2023] Open
Abstract
Aims We aimed to assess the impact of diabetes on sudden cardiac arrest (SCA) in US patients hospitalized for ST-elevation myocardial infarction (STEMI). Methods We used the National Inpatient Sample (2005-2017) data to identify adult patients with STEMI. The primary outcome was in-hospital SCA. Secondary outcomes included in-hospital mortality, ventricular tachycardia (VT), ventricular fibrillation (VF), cardiogenic shock (CS), acute renal failure (ARF), and the revascularization strategy in SCA patients. Results SCA significantly increased from 4% in 2005 to 7.6% in 2018 in diabetes patients and from 3% in 2005 to 4.6% in 2018 in non-diabetes ones (p < 0.001 for both). Further, diabetes was associated with an increased risk of SCA [aOR = 1.432 (1.336-1.707)]. In SCA patients with diabetes, the mean age (SD) decreased from 68 (13) to 66 (11) years old, and mortality decreased from 65.7% to 49.3% during the observation period (p < 0.001). Compared to non-diabetes patients, those with T2DM had a higher adjusted risk of mortality, ARF, and CS [aOR = 1.72 (1.62-1.83), 1.52 (1.43-1.63), 1.25 (1.17-1.33); respectively] but not VF or VT. Those patients were more likely to undergo revascularization with CABG [aOR = 1.197 (1.065-1.345)] but less likely to undergo PCI [aOR = 0.708 (0.664-0.754)]. Conclusion Diabetes is associated with an increased risk of sudden cardiac arrest in ST-elevation myocardial infarction. It is also associated with a higher mortality risk in SCA patients. However, the recent temporal mortality trend in SCA patients shows a steady decline, irrespective of diabetes.
Collapse
Affiliation(s)
- Omar Mhaimeed
- Johns Hopkins Hospital, Osler Medical Residency, Johns Hopkins University, Baltimore, MD, United States
- Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar
| | | | - Soha Dargham
- Biostatistics Core, Weill Cornell Medicine-Qatar, Doha, Qatar
| | | | - Hani Jneid
- Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX, United States
| | - Charbel Abi Khalil
- Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar
- Heart Hospital, Hamad Medical Corporation, Doha, Qatar
- Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, United States
| |
Collapse
|
3
|
Woodfield A, Gonzales T, Helmerhorst E, Laws S, Newsholme P, Porter T, Verdile G. Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer's Disease. Int J Mol Sci 2022; 23:ijms232415811. [PMID: 36555450 PMCID: PMC9779379 DOI: 10.3390/ijms232415811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Revised: 12/10/2022] [Accepted: 12/11/2022] [Indexed: 12/15/2022] Open
Abstract
Alzheimer's disease (AD) and type 2 diabetes (T2D) are chronic diseases that share several pathological mechanisms, including insulin resistance and impaired insulin signalling. Their shared features have prompted the evaluation of the drugs used to manage diabetes for the treatment of AD. Insulin delivery itself has been utilized, with promising effects, in improving cognition and reducing AD related neuropathology. The most recent clinical trial involving intranasal insulin reported no slowing of cognitive decline; however, several factors may have impacted the trial outcomes. Long-acting and rapid-acting insulin analogues have also been evaluated within the context of AD with a lack of consistent outcomes. This narrative review provided insight into how targeting insulin signalling in the brain has potential as a therapeutic target for AD and provided a detailed update on the efficacy of insulin, its analogues and the outcomes of human clinical trials. We also discussed the current evidence that warrants the further investigation of the use of the mimetics of insulin for AD. These small molecules may provide a modifiable alternative to insulin, aiding in developing drugs that selectively target insulin signalling in the brain with the aim to attenuate cognitive dysfunction and AD pathologies.
Collapse
Affiliation(s)
- Amy Woodfield
- Curtin Medical School, Curtin University, Bentley 6102, Australia
- Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Australia
| | - Tatiana Gonzales
- Curtin Medical School, Curtin University, Bentley 6102, Australia
| | - Erik Helmerhorst
- Curtin Medical School, Curtin University, Bentley 6102, Australia
- Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Australia
| | - Simon Laws
- Curtin Medical School, Curtin University, Bentley 6102, Australia
- Centre for Precision Health, Edith Cowan University, Joondalup 6027, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Australia
| | - Philip Newsholme
- Curtin Medical School, Curtin University, Bentley 6102, Australia
- Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Australia
| | - Tenielle Porter
- Curtin Medical School, Curtin University, Bentley 6102, Australia
- Centre for Precision Health, Edith Cowan University, Joondalup 6027, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Australia
| | - Giuseppe Verdile
- Curtin Medical School, Curtin University, Bentley 6102, Australia
- Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Australia
- School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Australia
- Correspondence: ; Tel.: +61-8-9266 5618
| |
Collapse
|
4
|
Katsiki N, Kazakos K, Triposkiadis F. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opin Pharmacother 2022; 23:1957-1974. [DOI: 10.1080/14656566.2022.2143263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Niki Katsiki
- Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece
- School of Medicine, European University Cyprus, Nicosia, Cyprus
| | - Kyriakos Kazakos
- Nursing Department, International Hellenic University, Thessaloniki, Greece
| | | |
Collapse
|
5
|
Carrondo MC. Diabetic women: Inpatient mortality risk before SARS-CoV-2. OBESITY MEDICINE 2022; 32:100413. [PMID: 35480137 PMCID: PMC9023087 DOI: 10.1016/j.obmed.2022.100413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 02/23/2022] [Accepted: 04/05/2022] [Indexed: 11/15/2022]
Abstract
Background Type 2 diabetes mellitus is a major driver of mortality worldwide. To assess the risk factors associated with diabetes that increase in-hospital mortality. Methods A retrospective cohort study was conducted using the National Hospital Morbidity with a sample of 3904 diabetic women admitted (2018–2019) in public hospitals, in Portugal. The type of comorbidities and the severity of the main disease – type 2 diabetes mellitus – was assessed based on the International Classification of Diseases (ICD-9) and Disease Staging. Cox proportional hazard was used to assess mortality during hospitalization. Mortality rates and mortality risk were the main outcome measures. Results In a total of 3904 diabetic women three hundred and eighty-nine (10.0%) died during hospitalization. Comorbidities bacterial pneumonia and coronary artery disease contributed 73% [Hazard ratio (HR) 1.73, 95% CI 1.32–2.27] and 37% [HR 1.37, 95% CI 1.03–1.81] respectively, to the risk of mortality, as did age over 65 years and severity 3 of the main disease. Conclusions Women with advanced type 2 diabetes mellitus, advanced age, and with comorbidities such as pneumonia and coronary artery disease admitted urgently have a higher risk of mortality during hospitalization.
Collapse
|
6
|
Chen NC, Chen CL, Shen FC. The Risk Factors of Severe Hypoglycemia in Older Patients with Dementia and Type 2 Diabetes Mellitus. J Pers Med 2022; 12:67. [PMID: 35055382 PMCID: PMC8779381 DOI: 10.3390/jpm12010067] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Revised: 12/29/2021] [Accepted: 01/05/2022] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The adequate glycemic control and risk factors for hypoglycemia in older patients with dementia and type 2 diabetes mellitus (T2DM) remain unclear. This study aimed to analyze the status of glycemic control and determine the risk of hypoglycemia among these groups. METHODS A hospital admission record due to hypoglycemia through an emergency room with glucose supplementation in the Chang Gung Memorial Hospital was identified as a hypoglycemic event. Patients with dementia and T2DM without hypoglycemic events throughout the study period were defined as the control group. We gathered patients aged ≥65 years with a diagnosis of Alzheimer's dementia (AD) and T2DM between 2001 and 2018 in the Chang Gung Research Database (CGRD). We extracted data included medication use, diagnoses, and biochemistry data from hospital records. RESULTS A total of 3877 older patients with dementia and T2DM with regular visits to the outpatient department were enrolled in this study. During the two-year follow-up period, 494 participants (12.7%) experienced hypoglycemia. Multivariable logistic multivariable regression models for hypoglycemic events showed that metformin had a protective effect (odds ratio (OR) = 0.75, p = 0.023), insulin had the highest risk (OR = 4.64, p < 0.001). Hemoglobin A1c (HbA1c) levels were not correlated with hypoglycemic events (OR = 0.95, p = 0.140). Patients with hypoglycemic episodes had a significantly higher proportion of ≥2 Charlson Comorbidity Index scores than those without hypoglycemic episodes (83.2% versus 56.4%, p < 0.001). CONCLUSIONS Drug regimen affects hypoglycemic episodes but not HbA1c in older patients with dementia and T2DM. In addition, patients with more comorbidities experience an increased risk of hypoglycemia.
Collapse
Affiliation(s)
- Nai-Ching Chen
- Department of Neurology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan;
| | - Chien-Liang Chen
- Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan;
- Division of Nephrology, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
- Department of Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
| | - Feng-Chih Shen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
- Center for Mitochondrial Research and Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan
| |
Collapse
|
7
|
Katsiki N, Fonseca V. Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer? J Diabetes Complications 2021; 35:108075. [PMID: 34656423 DOI: 10.1016/j.jdiacomp.2021.108075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Accepted: 10/04/2021] [Indexed: 11/20/2022]
Affiliation(s)
- Niki Katsiki
- First Department of Internal Medicine, Diabetes Center, Division of Endocrinology and Metabolism, AHEPA University Hospital, Thessaloniki, Greece.
| | - Vivian Fonseca
- Section of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States of America
| |
Collapse
|
8
|
Serban D, Balasescu SA, Alius C, Balalau C, Sabau AD, Badiu CD, Socea B, Trotea AM, Dascalu AM, Motofei I, Ardeleanu V, Spataru RI, Sabau D, Smarandache GC. Clinical and therapeutic features of acute cholecystitis in diabetic patients. Exp Ther Med 2021; 22:758. [PMID: 34035855 DOI: 10.3892/etm.2021.10190] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 03/03/2021] [Indexed: 12/12/2022] Open
Abstract
The present study aimed to compare the clinical, paraclinical, intraoperative findings, and postoperative complications in acute cholecystitis in diabetic patients vs. non-diabetic patients. A 2-year retrospective study was performed on the patients who underwent emergency cholecystectomy for acute cholecystitis between 2017 and 2019 at the 4th Department of Surgery, Emergency University Hospital Bucharest. The diabetic subgroup numbered 46 eligible patients and the non-diabetic one 287 patients. Demographics, the severity of the clinical forms, biological variables (including white cell count, urea, creatinine, coagulation and liver function tests) comorbidity status, surgical approach, postoperative complications, and hospital stay were analyzed. Statistical analyses were performed to assess comparative results between the aforementioned data (SPSS V 13.0). The CCI and ASA risk classes were increased in the diabetic group, with 34.78% of patients having 3 or more associated comorbidities. No statistically significant associations were demonstrated between diabetes and the severity of the cholecystitis and risk for conversion. Postoperatively both minor complications such as surgical site infections and major cardiovascular events were more common in the diabetic subgroup (P=0.0254), well associated with the preoperative status and baseline cardiovascular comorbidities. Laparoscopic cholecystectomy is a safe procedure for diabetic patients, which can provide the best outcomes, by decreasing the risks of surgical wounds. Attentive perioperative care and good glycemic control must be provided to minimize the risk of complications.
Collapse
Affiliation(s)
- Dragos Serban
- 4th Surgery Department, Emergency University Hospital Bucharest, 050098 Bucharest, Romania.,Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania
| | | | - Catalin Alius
- 4th Surgery Department, Emergency University Hospital Bucharest, 050098 Bucharest, Romania
| | - Cristian Balalau
- Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania.,Department of Surgery, 'Sf. Pantelimon' Emergency Hospital, 021659 Bucharest, Romania
| | - Alexandru Dan Sabau
- 3rd Clinical Department, Faculty of Medicine, 'Lucian Blaga' University Sibiu, 550169 Sibiu, Romania
| | - Cristinel Dumitru Badiu
- Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania
| | - Bogdan Socea
- Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania.,Department of Surgery, 'Sf. Pantelimon' Emergency Hospital, 021659 Bucharest, Romania
| | - Andra Maria Trotea
- Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania
| | - Ana Maria Dascalu
- Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania
| | - Ion Motofei
- Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania.,Department of Surgery, 'Sf. Pantelimon' Emergency Hospital, 021659 Bucharest, Romania
| | - Valeriu Ardeleanu
- The Faculty of Medicine, Doctoral School, 'Ovidius' University, 900527 Constanta, Romania.,Department of Surgery, General Hospital CFR, 800223 Galati, Romania.,Department of Plastic Surgery, Arestetic Clinic, BR4A, 800108 Galati, Romania
| | - Radu Iulian Spataru
- Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania.,Department of Pediatric Surgery, Emergency Clinic Hospital for Children 'Marie S. Curie', 077120 Bucharest, Romania
| | - Dan Sabau
- 3rd Clinical Department, Faculty of Medicine, 'Lucian Blaga' University Sibiu, 550169 Sibiu, Romania
| | - Gabriel Catalin Smarandache
- 4th Surgery Department, Emergency University Hospital Bucharest, 050098 Bucharest, Romania.,Faculty of Medicine, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania
| |
Collapse
|
9
|
Anagnostis P, Goulis DG, Mikhailidis DP. Endocrine Disease as a Cause of Cardiovascular Disease: Current Perspectives. Curr Pharm Des 2021; 26:5547-5550. [PMID: 33272168 DOI: 10.2174/1381612826666201203115443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Panagiotis Anagnostis
- Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Dimitrios G Goulis
- Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Dimitri P Mikhailidis
- Department of Clinical Biochemistry and Department of Surgery, Royal Free Hospital Campus, University College Medical School, University College London, London, United Kingdom
| |
Collapse
|